Follow-on Biologics: Is Your Patent Portfolio Ready?
19 December 2012
Recent health insurance reform legislation made headlines throughout the United States for its sweeping reforms to how Americans will receive their health care. Less-noticed was that Congress and the President also created the legal and regulatory framework for the approval of follow-on biologics.
To continue reading this article, please Login or Register to be a subscriber
